PSA velocity no better than latest PSA value in screening men carrying BRCA1/2 genes

Data from the ongoing, prospective IMPACT study has shown that PSA velocity is not predictive of risk for a positive prostate cancer biopsy result in men who are carriers of the BRCA2 gene. … READ MORE …

Second PARP inhibitor approved by FDA (but still not for prostate cancer)

A second PARP inhibitor has recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with BRCA1/2 mutations and advanced ovarian cancer who have already received two types of chemotherapy. … READ MORE …

Poorer outcomes for BRCA1/2 carriers after standard treatment

It is not entirely surprising to come across a paper suggesting that male carriers of the BRCA1/2 genes are at risk for worse post-treatment outcomes than non-carriers of these genes after standard forms of first-line treatment for prostate cancer. … READ MORE …